See more : Svenska Cellulosa Aktiebolaget SCA (publ) (SCA-A.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Suzuken Co., Ltd. (SZUKF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Suzuken Co., Ltd., a leading company in the Medical – Distribution industry within the Healthcare sector.
- AB Traction (TRAC-B.ST) Income Statement Analysis – Financial Results
- Dongkuk Steel Mill Company Limited (001230.KS) Income Statement Analysis – Financial Results
- Citycon Oyj (COYJF) Income Statement Analysis – Financial Results
- Moury Construct SA (MOUR.BR) Income Statement Analysis – Financial Results
- United Community Banks, Inc. (UCBIO) Income Statement Analysis – Financial Results
Suzuken Co., Ltd. (SZUKF)
About Suzuken Co., Ltd.
Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,386.49B | 2,314.83B | 2,232.77B | 2,128.48B | 2,213.53B | 2,132.35B | 2,124.02B | 2,127.08B | 2,228.20B | 1,969.68B | 1,988.14B | 1,894.61B | 1,859.93B | 1,751.96B | 1,735.48B | 1,641.39B | 1,586.58B | 1,454.84B | 1,388.69B | 1,330.98B |
| Cost of Revenue | 2,201.24B | 2,135.13B | 2,071.78B | 1,970.64B | 2,019.41B | 1,943.05B | 1,936.50B | 1,933.85B | 2,025.74B | 1,790.05B | 1,802.08B | 1,719.60B | 1,690.20B | 1,586.77B | 1,565.89B | 1,479.32B | 1,422.54B | 1,306.48B | 1,248.26B | 1,201.97B |
| Gross Profit | 185.25B | 179.70B | 160.99B | 157.84B | 194.12B | 189.30B | 187.51B | 193.23B | 202.46B | 179.63B | 186.06B | 175.02B | 169.74B | 165.19B | 169.59B | 162.07B | 164.04B | 148.36B | 140.44B | 129.01B |
| Gross Profit Ratio | 7.76% | 7.76% | 7.21% | 7.42% | 8.77% | 8.88% | 8.83% | 9.08% | 9.09% | 9.12% | 9.36% | 9.24% | 9.13% | 9.43% | 9.77% | 9.87% | 10.34% | 10.20% | 10.11% | 9.69% |
| Research & Development | 0.00 | 2.95B | 4.59B | 3.45B | 4.65B | 5.87B | 6.67B | 7.64B | 5.71B | 5.70B | 5.97B | 5.60B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 133.26B | 130.92B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 129.95B | 123.72B | 116.71B |
| Selling & Marketing | 17.12B | 16.17B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 150.37B | 147.09B | 147.22B | 148.68B | 161.55B | 162.07B | 161.10B | 166.87B | 168.51B | 166.39B | 168.22B | 163.74B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 129.95B | 123.72B | 116.71B |
| Other Expenses | 0.00 | 1.07B | 7.92B | 7.45B | 7.23B | 7.16B | 7.26B | 6.99B | 15.39B | 14.71B | 15.47B | 14.32B | 14.89B | 14.08B | 13.92B | 13.04B | 12.95B | 10.67B | 12.51B | 10.75B |
| Operating Expenses | 150.37B | 147.09B | 147.22B | 148.68B | 161.55B | 162.07B | 167.78B | 174.51B | 174.22B | 166.39B | 168.22B | 163.74B | 162.18B | 159.82B | 155.52B | 147.38B | 140.79B | 129.95B | 123.72B | 116.71B |
| Cost & Expenses | 2,351.62B | 2,282.22B | 2,219.00B | 2,119.32B | 2,180.96B | 2,105.12B | 2,104.28B | 2,108.36B | 2,199.96B | 1,956.44B | 1,970.30B | 1,883.33B | 1,852.38B | 1,746.59B | 1,721.41B | 1,626.71B | 1,563.33B | 1,436.43B | 1,371.98B | 1,318.68B |
| Interest Income | 166.00M | 171.00M | 196.00M | 167.00M | 236.00M | 289.00M | 357.00M | 459.00M | 574.00M | 666.00M | 720.00M | 702.00M | 716.00M | 725.00M | 730.00M | 1.13B | 1.00B | 1.15B | 436.00M | 368.00M |
| Interest Expense | 43.00M | 42.00M | 51.00M | 49.00M | 53.00M | 55.00M | 58.00M | 54.00M | 50.00M | 32.00M | 22.00M | 23.00M | 43.00M | 81.00M | 79.00M | 43.00M | 47.00M | 27.00M | 110.00M | 65.00M |
| Depreciation & Amortization | 8.74B | 8.84B | 10.02B | 10.31B | 11.43B | 11.56B | 12.06B | 12.70B | 11.93B | 11.72B | 11.93B | 12.24B | 10.98B | 9.66B | 8.21B | 7.07B | 6.57B | 5.72B | 5.52B | 5.24B |
| EBITDA | 51.40B | 39.48B | 32.55B | 22.92B | 53.29B | 57.09B | 40.89B | 45.05B | 40.17B | 41.26B | 29.77B | 35.61B | 28.24B | 27.98B | 33.48B | 20.77B | 44.30B | 36.45B | 34.44B | 27.56B |
| EBITDA Ratio | 2.15% | 1.95% | 1.48% | 1.34% | 2.36% | 2.20% | 1.89% | 1.86% | 2.59% | 2.12% | 2.38% | 2.10% | 1.84% | 1.70% | 2.13% | 2.19% | 2.76% | 2.48% | 2.53% | 2.15% |
| Operating Income | 34.88B | 32.61B | 13.78B | 9.16B | 32.57B | 27.23B | 19.74B | 18.71B | 28.24B | 13.24B | 17.84B | 11.28B | 7.56B | 5.37B | 14.07B | 14.68B | 23.25B | 18.41B | 16.72B | 12.30B |
| Operating Income Ratio | 1.46% | 1.41% | 0.62% | 0.43% | 1.47% | 1.28% | 0.93% | 0.88% | 1.27% | 0.67% | 0.90% | 0.60% | 0.41% | 0.31% | 0.81% | 0.89% | 1.47% | 1.27% | 1.20% | 0.92% |
| Total Other Income/Expenses | 7.92B | -2.01B | 2.37B | 3.40B | 9.24B | 18.25B | 9.03B | 13.59B | 16.77B | 16.27B | 17.94B | 12.07B | 8.31B | 11.29B | 11.12B | -1.02B | 14.43B | 12.30B | 12.01B | 9.95B |
| Income Before Tax | 42.79B | 30.59B | 22.48B | 12.56B | 41.81B | 45.48B | 28.77B | 32.30B | 45.02B | 29.51B | 35.78B | 23.35B | 15.87B | 16.66B | 25.19B | 13.66B | 37.68B | 30.71B | 28.81B | 22.25B |
| Income Before Tax Ratio | 1.79% | 1.32% | 1.01% | 0.59% | 1.89% | 2.13% | 1.35% | 1.52% | 2.02% | 1.50% | 1.80% | 1.23% | 0.85% | 0.95% | 1.45% | 0.83% | 2.38% | 2.11% | 2.07% | 1.67% |
| Income Tax Expense | 13.79B | 10.28B | 8.01B | 4.56B | 13.53B | 15.10B | 9.82B | 10.91B | 16.00B | 10.54B | 14.29B | 8.98B | 7.79B | 7.01B | 10.84B | 6.09B | 16.14B | 12.88B | 11.26B | 9.46B |
| Net Income | 29.02B | 20.35B | 14.39B | 7.90B | 28.21B | 30.20B | 18.82B | 21.31B | 28.96B | 18.92B | 21.45B | 14.35B | 8.05B | 9.63B | 13.97B | 7.07B | 21.33B | 17.70B | 17.18B | 12.58B |
| Net Income Ratio | 1.22% | 0.88% | 0.64% | 0.37% | 1.27% | 1.42% | 0.89% | 1.00% | 1.30% | 0.96% | 1.08% | 0.76% | 0.43% | 0.55% | 0.80% | 0.43% | 1.34% | 1.22% | 1.24% | 0.94% |
| EPS | 357.87 | 236.46 | 163.18 | 88.51 | 310.26 | 322.72 | 198.21 | 216.92 | 292.13 | 190.82 | 216.30 | 144.72 | 81.18 | 97.08 | 140.87 | 70.09 | 209.54 | 174.29 | 170.38 | 92.05 |
| EPS Diluted | 357.87 | 236.46 | 163.18 | 88.51 | 310.26 | 322.72 | 198.21 | 216.92 | 292.13 | 190.82 | 216.30 | 144.72 | 81.18 | 97.08 | 140.87 | 70.09 | 209.54 | 174.29 | 170.38 | 91.88 |
| Weighted Avg Shares Out | 81.08M | 86.04M | 88.20M | 89.19M | 90.93M | 93.59M | 94.95M | 98.23M | 99.14M | 99.16M | 99.16M | 99.16M | 99.16M | 99.17M | 99.17M | 100.90M | 101.78M | 101.57M | 100.86M | 100.73M |
| Weighted Avg Shares Out (Dil) | 81.08M | 86.04M | 88.20M | 89.19M | 90.93M | 93.59M | 94.95M | 98.23M | 99.14M | 99.16M | 99.16M | 99.16M | 99.16M | 99.17M | 99.17M | 100.90M | 101.78M | 101.57M | 100.86M | 136.87M |
Source: https://incomestatements.info
Category: Stock Reports